CSL Behring recently opened a new, 300-million-franc ($332 million US) state-of-the-art manufacturing facility in the heart of Bern, Switzerland. This facility was expanded to produce immunoglobulins – an important treatment for people who have serious and rare diseases.
CSL Behring had a small celebration to mark the grand opening of the facility. In attendance were Federal Council Member Ueli Maurer; State Council President Pierre Alain Schnegg; and Mayor Alec von Graffenried. Martin Schaeren, CSL Behring’s Senior Vice President & General Manager in Bern, praised the project team and said regulatory approval for the new facility is expected in spring of 2021.